Trials / Completed
CompletedNCT03742921
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
ISTODAX® for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Istodax | Istodax |
Timeline
- Start date
- 2019-02-04
- Primary completion
- 2023-10-31
- Completion
- 2023-10-31
- First posted
- 2018-11-15
- Last updated
- 2023-12-06
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03742921. Inclusion in this directory is not an endorsement.